Evidence map›Paper›PMID 28755088›Full record

SynthesisBreast cancer (Tokyo, Japan)2018

Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.

Zhu Yu, Xiaojing Guo, Yicheng Jiang, Lei Teng, Jinwu Luo, Pengfei Wang, Yunsheng Liang, Haitian Zhang

Open access · hybridAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Breast cancer (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Effectiveness of Pilates and circuit-based exercise in reducing arthralgia in women during hormone therapy for breast cancer: a randomized, controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Trial
  3. Cancer Stem Cells: Current Challenges and Future Perspectives.Methods in molecular biology (Clifton, N.J.) · 2024
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zhu YuDepartment of Gastrointestinal and Gland Surgery, Sino-Germany Standard Diagnosis and Treatment Center of Breast Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Xiaojing GuoDepartment of Gastrointestinal and Gland Surgery, Sino-Germany Standard Diagnosis and Treatment Center of Breast Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Yicheng JiangDepartment of Gastrointestinal and Gland Surgery, Sino-Germany Standard Diagnosis and Treatment Center of Breast Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Lei TengDepartment of Gastrointestinal and Gland Surgery, Sino-Germany Standard Diagnosis and Treatment Center of Breast Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Jinwu LuoDepartment of Gastrointestinal and Gland Surgery, Sino-Germany Standard Diagnosis and Treatment Center of Breast Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Pengfei WangDepartment of Gastrointestinal and Gland Surgery, Sino-Germany Standard Diagnosis and Treatment Center of Breast Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Yunsheng LiangDepartment of Gastrointestinal and Gland Surgery, Sino-Germany Standard Diagnosis and Treatment Center of Breast Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Haitian ZhangDepartment of Gastrointestinal and Gland Surgery, Sino-Germany Standard Diagnosis and Treatment Center of Breast Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. zhanghaitian@msn.com.ORCID http://orcid.org/0000-0003-3405-6013
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn patients with hormone receptor-positive postmenopausal of early stage breast cancer, adjuvant endocrine monotherapies include letrozole, anastrozole, exemestane, toremifene and tamoxifen. But the optimum regimen remains controversial.

methodsPubMed, Cochrane Database and ClinicalTrials.gov were systematically reviewed of abstract for randomized-controlled trials (RCTs) to assess the efficacy of tamoxifen, letrozole, exemestane, anastrozle and toremifene for postmenopausal patients with hormone-receptor positive (HR+), who have not received prior therapy for early stage breast cancer. The outcomes were measured by disease-free survival (DFS) and overall survival (OS). We evaluated relative hazard ratios (HRs) for death of different therapies by combination hazard ratios for death of included trials. The SUCRA values were used to evaluate the rankings of efficacy for these monotherapies.

resultsA total of fourteen studies including 19,517 patients in our research were absorbed and estimated. The superiority of efficacy for DFS were 5-year letrozole and 10-year tamoxifen (SUCRA values 0.743/0.657) in all comparisons. A more efficient SUCRA values for OS were 5-year Exemestane, 5-year letrozole and 10-year tamoxifen (0.756/0.677/0.669).

conclusionsClinically important differences exist between commonly prescribed different adjuvant endocrine monotherapy regimens for both efficacy and acceptability in favor of exemestane and letrozole. 10-year tamoxifen for early breast cancer patients is noninferior to 5-year anastrozle, and might be the best choice where aromatase inhibitors (AIs) are not easy to acquire.

Indexed as

PostmenopauseAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleHumansPrognosisReceptors, EstrogenReceptors, ProgesteroneAromatase InhibitorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneEarly breast cancerEndocrine monotherapyNetwork meta-analysisPostmenopausal women

Identifiers

PMID28755088
PMCPMC5741789
OpenAlexW2740899167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.